imatinib has been researched along with Gastrointestinal Stromal Tumors in 8 studies
Gastrointestinal Stromal Tumors: All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity." | 5.46 | Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). ( Li, J; Li, X; Lu, Y; Mao, F; Wang, M; Xu, Q; Zheng, X; Zhu, J, 2017) |
| " Here we describe the identification of potent pan-KIT mutant kinase inhibitors that can be dosed without being limited by the tolerability issues seen with multitargeted agents." | 1.48 | Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. ( Anjum, R; Barry, E; Bhavsar, D; Boyd, S; Brown, C; Campbell, A; Goldberg, K; Grondine, M; Guichard, S; Hardy, CJ; Hunt, T; Jones, RDO; Kettle, JG; Li, X; Moleva, O; Ogg, D; Overman, RC; Packer, MJ; Pearson, S; Schimpl, M; Shao, W; Smith, A; Smith, JM; Stead, D; Stokes, S; Tucker, M; Ye, Y, 2018) |
| "9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity." | 1.46 | Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). ( Li, J; Li, X; Lu, Y; Mao, F; Wang, M; Xu, Q; Zheng, X; Zhu, J, 2017) |
| " In addition, 13 possessed acceptable bioavailability (36%) and effectively suppressed the tumor growth in GIST-T1 cell inoculated xenograft model without apparent toxicity." | 1.43 | Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). ( Chen, C; Hu, Z; Liu, F; Liu, J; Liu, Q; Liu, X; Qi, S; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, Q; Wang, W; Wang, Y; Zhang, S; Zhao, Z; Zou, F, 2016) |
| " In the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model, 35 exhibited dose dependent tumor growth suppression efficacy and 100 mg/kg dosage provided 47." | 1.43 | Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kina ( Bai, M; Chen, C; Hu, C; Hu, Z; Li, B; Liu, F; Liu, J; Liu, Q; Liu, X; Qi, Z; Ren, T; Wang, A; Wang, B; Wang, L; Wang, W; Wu, H; Wu, J; Ye, L; Yu, K; Zhang, S; Zou, F, 2016) |
| "Most of human gastrointestinal stromal tumors (GIST) are driven by activating mutations in the proto-oncogene KIT, a tyrosine kinase receptor." | 1.35 | Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. ( Beltran, M; Cuenca, F; Fletcher, JA; Galesa, K; Gunaratnam, M; Haider, SM; Neidle, S; Reszka, AP; Swank, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gunaratnam, M | 1 |
| Swank, S | 1 |
| Haider, SM | 1 |
| Galesa, K | 1 |
| Reszka, AP | 1 |
| Beltran, M | 1 |
| Cuenca, F | 1 |
| Fletcher, JA | 1 |
| Neidle, S | 1 |
| Wang, Q | 1 |
| Liu, F | 2 |
| Wang, B | 3 |
| Zou, F | 3 |
| Chen, C | 3 |
| Liu, X | 3 |
| Wang, A | 3 |
| Qi, S | 1 |
| Wang, W | 5 |
| Qi, Z | 3 |
| Zhao, Z | 1 |
| Hu, Z | 3 |
| Wang, L | 3 |
| Zhang, S | 3 |
| Wang, Y | 1 |
| Liu, J | 4 |
| Liu, Q | 4 |
| Li, B | 1 |
| Yu, K | 2 |
| Wu, H | 1 |
| Hu, C | 2 |
| Wu, J | 1 |
| Ye, L | 1 |
| Ren, T | 2 |
| Bai, M | 2 |
| Lu, Y | 1 |
| Mao, F | 1 |
| Li, X | 2 |
| Zheng, X | 1 |
| Wang, M | 1 |
| Xu, Q | 1 |
| Zhu, J | 1 |
| Li, J | 1 |
| Kettle, JG | 1 |
| Anjum, R | 1 |
| Barry, E | 1 |
| Bhavsar, D | 1 |
| Brown, C | 1 |
| Boyd, S | 1 |
| Campbell, A | 1 |
| Goldberg, K | 1 |
| Grondine, M | 1 |
| Guichard, S | 1 |
| Hardy, CJ | 1 |
| Hunt, T | 1 |
| Jones, RDO | 1 |
| Moleva, O | 1 |
| Ogg, D | 1 |
| Overman, RC | 1 |
| Packer, MJ | 1 |
| Pearson, S | 1 |
| Schimpl, M | 1 |
| Shao, W | 1 |
| Smith, A | 1 |
| Smith, JM | 1 |
| Stead, D | 1 |
| Stokes, S | 1 |
| Tucker, M | 1 |
| Ye, Y | 1 |
| Wu, TS | 2 |
| Lin, WH | 2 |
| Tsai, HJ | 2 |
| Hsueh, CC | 2 |
| Hsu, T | 2 |
| Wang, PC | 2 |
| Lin, HY | 2 |
| Peng, YH | 2 |
| Lu, CT | 2 |
| Lee, LC | 1 |
| Tu, CH | 1 |
| Kung, FC | 2 |
| Shiao, HY | 2 |
| Yeh, TK | 2 |
| Song, JS | 2 |
| Chang, JY | 1 |
| Su, YC | 2 |
| Chen, LT | 2 |
| Chen, CT | 2 |
| Jiaang, WT | 2 |
| Wu, SY | 2 |
| Wang, J | 1 |
| Ge, J | 1 |
| Jiang, Z | 1 |
| Kuo, CC | 1 |
| Chen, CP | 1 |
| Weng, YL | 1 |
| Wu, MH | 1 |
| Huang, KW | 1 |
| Chou, LH | 1 |
| Yen, KJ | 1 |
| Kuo, PC | 1 |
| Huang, CL | 1 |
| Shih, C | 1 |
8 other studies available for imatinib and Gastrointestinal Stromal Tumors
| Article | Year |
|---|---|
Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule.
Topics: Base Sequence; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dose-Response Relationship | 2009 |
Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).
Topics: Administration, Oral; Animals; Area Under Curve; Benzamides; Cell Line, Tumor; Drug Discovery; Gastr | 2016 |
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kina
Topics: Amides; Animals; Cell Line, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumo | 2016 |
Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Resistance, | 2017 |
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
Topics: Drug Discovery; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Models, Molecul | 2018 |
Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Evaluatio | 2019 |
Discovery of ( E)- N
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug R | 2019 |
Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; G | 2019 |